Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Income Statement [Abstract]
Revenue	$ 143,370	$ 156,473	$ 181,157
Cost of goods sold	52,284	64,550	59,828
Gross profit	91,086	91,923	121,329
Operating expenses:
Research and development	18,104	20,793	21,019
Clinical and regulatory affairs	14,036	13,851	12,952
Marketing and sales	64,673	76,855	92,400
General and administrative	35,984	43,477	35,301
Restructuring costs	838	3,270	1,477
Contract termination, product withdrawal and business acquisition expenses	0	1,869	0
Total operating expenses	133,635	160,115	163,149
Loss from operations	(42,549)	(68,192)	(41,820)
Other income (expense):
Interest income	6	10	83
Interest expense	(34,973)	(27,658)	(22,064)
Change in fair value of contingent consideration related to acquisition	1,700	7,100	2,900
Loss on debt extinguishment	(11,756)	(2,270)	(6,512)
Change in fair value of derivative liabilities	17,713	12,097	0
Other (expense) income, net	377	(517)	554
Total other expense, net	(26,933)	(11,238)	(25,039)
Net loss before income taxes	(69,482)	(79,430)	(66,859)
Income tax (expense) benefit	4,725	(284)	459
Net loss	(64,757)	(79,714)	(66,400)
Comprehensive loss, net of taxes:
Net loss	(64,757)	(79,714)	(66,400)
Other comprehensive (loss) income on foreign currency translation	(772)	(747)	1,847
Comprehensive loss	$ (65,529)	$ (80,461)	$ (64,553)
Basic and diluted net loss per share (in USD per share)	$ (3.84)	$ (9.07)	$ (7.97)
Shares used in computing basic and diluted net loss per share (in shares)	16,850	8,790	8,333